Xpert® Breast Cancer STRAT4

Home / Tests / Oncology & Human Genetics

Standardized breast cancer ESR1/PGR/ERBB2/MKi67 mRNA biomarker assessment in less than two hours

Test pack size(s)

10 Tests

GXBCSTRAT4-CE-10

Qty

Unit price

Subtotal

USD

1 Tests

GXFFPE-LYSIS-CE-10

Qty

Unit price

Subtotal

USD

Total

Error adding items to cart. If this error persists, please contact Digital Support

List name

Label

Having trouble? Contact Cepheid Digital Support

The Need

Breast cancer biomarker ER/PGR/HER2/Ki-67 results need to be dependable and objective

Clinicians need more reliable ER/PGR/HER2/Ki-67 assessment in FFPE tumor tissues.
5% of HER2 IHC results are equivocal based upon guide line recommended classifications.¹
Resolving HER2 IHC2+ equivocal results with FISH is challenging.^1-4
Technical and observer variability can lead to approximately 20% inaccurate ER and PGR results.⁵
Ki-67 IHC scores deviate due to a lack of standardization.⁶

(1)Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor
(2)Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
(3)Starczynski J et al. HER2 Gene Amplification in Breast Cancer. A Rogues' Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations. AM J Clin Pathol. 2012 Apr;137(4):595-605.
(4)Rakha A et al. Updated UK Recommendations for HER2 assessment in breast cancer. Clin Pathol. 2015 Feb;68(2):93-99.
(5)Hammond MEH et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Onc. 2010 Feb 23; 28(16): 2784-2795.
(6)Polley MYC et a.l An International Ki67 Reproducibility Study. J Natl Cancer Ins. 2013 Dec 18;105(24):1897-906.

The Solution

Xpert Breast Cancer STRAT4 supports standardized ER/PGR/HER2/Ki‑67 mRNA assessment in less than 2 hours.

Xpert Breast Cancer STRAT4 delivers semi-quantitative determination of ER/PGR/HER2/Ki-67 mRNA levels in FFPE invasive breast cancer sections
- CYFIP1* reference gene is used for sample normalization
- Three controls included in each test
- Software report allows for objective and easy result interpretation

CYFIP1: Cytoplasmic FMR1 interacting protein 1

The Impact

Fast, clear, and accurate results by STRAT4 can help laboratories in diverse settings address various challenges with IHC/ISH testing to aid in the clinical evaluation of patients. ⁶
May facilitate a cost-efficient, quick, easy, and quality solution in labs facing challenges with IHC.^7-9
Enables decentralized testing that doesn’t require a PCR laboratory to support breast cancer testing in low- and middle-income countries. ^6,7,9

(7)Xpert^® Breast Cancer STRAT4 Package Insert. Sunnyvale. USA. 2017
(8)Gnant M et al. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care. 2015 Apr;10(2):124-130.
(9)Senkus et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v8-30.# For Research Use Only. Not for use in diagnostic procedures.* CE-IVD. In Vitro Medical Device. Not available in the U.S. Not available in all countries.^ Limited to one per customer.